Heart Failure with Preserved Ejection Fraction in Cancer Patients and Survivors. A Scientific Statement of the Heart Failure Association of the ESC and the ESC Council of Cardio-Oncology
Kalliopi Keramida(National and Kapodistrian University of Athens), Gerasimos Filippatos(National and Kapodistrian University of Athens), Ninian N. Lang(British Heart Foundation), Mark C. Petrie(British Heart Foundation), Gianluigi Savarese(Karolinska Institutet), Amina Rakisheva(Esteve Química (Spain)), Pietro Ameri(Ospedale Policlinico San Martino), Borja Ibáñez(Spanish National Centre for Cardiovascular Research), Anita Deswal(The University of Texas MD Anderson Cancer Center), Mariana Mirabel, Carlo G. Tocchetti(Federico II University Hospital), Dimitrios Farmakis(National and Kapodistrian University of Athens), Alexander R. Lyon(Royal Brompton Hospital), Carolyn S.P. Lam(University of Glasgow), Brenda Moura(Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo), Jutta Bergler‐Klein, Walter J. Paulus(Amsterdam Neuroscience), Marco Metra(Vita-Salute San Raffaele University), Markus S. Anker(Humboldt-Universität zu Berlin), Michele Senni(Ospedale Papa Giovanni XXIII), Teresa López‐Fernández(Hospital Universitario La Paz)
Cited by 8
Related Papers
2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure
|European Heart Journal|2021|13.1k
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
|New England Journal of Medicine|2019|6.8k
Empagliflozin in Heart Failure with a Preserved Ejection Fraction
|New England Journal of Medicine|2021|4.6k
ESC/EAS Guidelines for the management of dyslipidaemias: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS)
|European Heart Journal|2011|3.5k
ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008
|European Journal of Heart Failure|2008|3.5k